Margenza

Active Ingredient(s): Margetuximab-cmkb
FDA Approved: * December 16, 2020
Pharm Company: * MACROGENICS INC
Category: Cancer

Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.[3][4] The most common adverse drug reactions in combination with chemotherapy are fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, infusion-related reactions, palmar-plantar erythrodys... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.